AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT04193059 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Trastuzumab
Description: trastuzumab 6 mg/kg (loading dose 8mg/kg) ivgtt d1, 21 days per cycle with chemotherapy; or trastuzumab 2 mg/kg (loading dose 4mg/kg, w1) ivgtt d1, d8, d15, d22, 28 days per cycle with chemotherapy. After chemotherapy, patient will continue to complete 1 year of adjuvant trastuzumab (6 mg/kg ivgtt every 3 weeks).
Study NCT04193059 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Trastuzumab
Description: trastuzumab 6 mg/kg (loading dose 8mg/kg) ivgtt d1, 21 days per cycle with chemotherapy; or trastuzumab 2 mg/kg (loading dose 4mg/kg, w1) ivgtt d1, d8, d15, d22, 28 days per cycle with chemotherapy. After chemotherapy, patient will continue to complete 1 year of adjuvant trastuzumab (6 mg/kg ivgtt every 3 weeks).
Study NCT04193059 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Pertuzumab
Description: pertuzumab 420mg (loading dose 840mg) ivgtt d1, 21 days per cycle with chemotherapy. After chemotherapy, patient will continue to complete 1 year of adjuvant pertuzumab (420mg ivgtt every 3 weeks).
Study NCT04193059 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pertuzumab
Description: pertuzumab 420mg (loading dose 840mg) ivgtt d1, 21 days per cycle with chemotherapy. After chemotherapy, patient will continue to complete 1 year of adjuvant pertuzumab (420mg ivgtt every 3 weeks).
Study NCT04193059 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Docetaxel
Description: docetaxel 100 mg/m\^2 ivgtt d1, 21 days per cycle, 4 cycles.
Study NCT02109926 — intervention group
Intervention type: OTHER
Intervention: Phone interview and blood test
Description: Subjects will be interviewed about environmental, domestic and occupational exposures during several periods of life Two blood samples will be collected at enrollment to study genetic polymorphisms
Study NCT05886699 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: PRP combined with DFDBA
Description: Periodontal intrabony defects were treated with open flap debridement followed by placement of PRP combined with DFDBA
Study NCT05886699 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: DFDBA
Description: Periodontal intrabony defects were treated with open flap debridement followed by placement of PRP combined with DFDBA
Study NCT03010085 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Open left-sided hepatectomy
Description: Open left-sided hepatectomy Laparotomy (upper midline, inverted 'L', or Benz incision) Mobilization of the liver Glissonian approach or individual isolation technique Left lateral sectionectomy or left hemihepatectomy
Study NCT03010085 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Laparoscopic left-sided hepatectomy
Description: Trocar insertion Mobilization of the liver Glissonian approach or individual isolation technique Left lateral sectionectomy or left hemihepatectomy
Study NCT01331785 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Midodrine
Description: Midodrine 2.5 mg to 10 mg three times a day to increase systolic BP above 100 mmHgor by 10 mmHg
Study NCT04478071 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: vadadustat
Description: Participants will receive vadadustat once daily for 14 days.
Study NCT04478071 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: Participants will receive matching placebo once daily for 14 days.
Study NCT01677910 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Telotristat etiprate
Description: Telotristat etiprate tablets.
Study NCT03912259 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dupilumab
Description: Pharmaceutical form: solution,~Route of administration: SC
Study NCT01677910 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo-matching telotristat etiprate
Description: Placebo-matching telotristat etiprate tablets.
Study NCT01677910 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo-matching telotristat etiprate
Description: Placebo-matching telotristat etiprate tablets.
Study NCT02909725 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Limit accumulation of sedentary time
Description: Participants in this group receive a Fitbit Alta activity monitor, worn on the wrist for the entire intervention. The Alta is a fitness tracker designed to help individuals track their sedentary and physical activity behaviors when paired with an external device (e.g. iPhone, computer). The Sensewear armband and ActivPAL are not worn as part of the intervention; they are assessment tools used at the beginning and end of the study.~Each participant will have a Fitbit account set up with a Blossom Project username code to ensure privacy of the participant's identity. Participants will be asked to achieve a goal of 250 steps/hour. Using the reminder to move function, if a participant has not reached the hourly goal at 50 minutes, the Alta will vibrate, cueing the participant to walk.
Study NCT02909725 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Walk
Description: Participants in this group receive a Fitbit Charge activity monitor. There is no reminder to move function on this band. The Charge, worn on the wrist for the entire intervention is a fitness tracker designed to help individuals track their physical activity when paired with an external device. The Sensewear armband and ActivPAL are not worn as part of the intervention; they are assessment tools used at the beginning and end of the study.~Each participant will have a Fitbit account set up with a Blossom Project username code to ensure privacy of the participant's identity. Participants will be asked to meet current pregnancy physical activity recommendations; walking 30 minutes, most days of the week (150 minutes/week). Participants can use the app to view their active minutes.
Study NCT02909725 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Normal daily routine; Usual Care
Description: Participants in this group will not be provided with a Fitbit Charge activity monitor, as participants will be asked to simply continue on with their normal daily routine. The Sensewear armband and ActivPAL are not worn as part of the intervention; they are assessment tools used at the beginning and end of the study.
Study NCT00580983 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: IMRT
Study NCT00580983 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Paclitaxel
Study NCT00580983 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Carboplatin
Study NCT00580983 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cisplatin
Study NCT00580983 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 5-Fluorouracil
Study NCT02775253 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Chronic cold acclimation
Study NCT04274192 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Synchronized HFNC at 6 liters per minute (LPM)
Description: HFNC given in synchrony with the subject's own respiratory effort using NAVA at 6 LPM
Study NCT04274192 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Synchronized HFNC at 6 liters per minute (LPM)
Description: HFNC given in synchrony with the subject's own respiratory effort using NAVA at 6 LPM
Study NCT04274192 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Continuous HFNC at 6 liters per minute (LPM)
Description: Standard HFNC therapy at 6 LPM
Study NCT04274192 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Continuous HFNC at 6 liters per minute (LPM)
Description: Standard HFNC therapy at 6 LPM
Study NCT04274192 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Synchronized HFNC at 8 liters per minute (LPM)
Description: HFNC given in synchrony with the subject's own respiratory effort using NAVA at 8 LPM
Study NCT04274192 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Synchronized HFNC at 8 liters per minute (LPM)
Description: HFNC given in synchrony with the subject's own respiratory effort using NAVA at 8 LPM
Study NCT01061775 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Exenatide
Description: 5mcg twice a day for 4 weeks increased to 10 mcg twice a day for 20 weeks.
Study NCT04274192 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Continuous HFNC at 8 liters per minute (LPM)
Description: Standard HFNC therapy at 8 LPM
Study NCT04274192 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Continuous HFNC at 8 liters per minute (LPM)
Description: Standard HFNC therapy at 8 LPM
Study NCT00203502 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bevacizumab
Description: IV 15mg/kg 21 days
Study NCT00203502 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cyclophosphamide
Description: 500mg per meter squared, IV every 21 days
Study NCT02658682 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Attention Bias Modification
Description: Computer based Attention Bias Modification
Study NCT02658682 — intervention group
Intervention type: BEHAVIORAL
Group type: SHAM_COMPARATOR
Intervention: Sham Attention Bias Modification
Description: Computer based Sham Attention Bias Modification
Study NCT01814579 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Unidirectional Barbed Suture (V-Loc)
Description: Patients enrolled in the Unidirectional Barbed Suture arm will have their vaginal cuff closed using this device during their robotic hysterectomy.
Study NCT03912259 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Pharmaceutical form: solution,~Route of administration: SC
Study NCT03912259 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Emollient (moisturizer)
Description: Pharmaceutical form: cream,~Route of administration: topical use
Study NCT00203502 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Docetaxel
Description: 60 mg per meter squared, IV every 21 days
Study NCT00597779 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Dynamic Hip Screw (DHS); Trochanteric Fixation Nail (TFN)
Description: Surgical stabilization of unstable intertrochanteric hip fractures using two commonly used implant categories
Study NCT03912259 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Emollient (moisturizer)
Description: Pharmaceutical form: cream,~Route of administration: topical use
Study NCT00791024 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CRC-Pharma 001
Description: 50 mg
Study NCT00791024 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: lidocaine suspension
Description: 5.0 ml lidocaine suspension(20mg/ml) adm. 10 min. before oesophagogastroduodenoscopy.
Study NCT01814579 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: polyglactin 910 (Vicryl)
Description: Patients in the Smooth Suture arm will have their vaginal cuff closed with this device during their robotic hysterectomy.
Study NCT00826631 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Fast food arm
Description: Doubling of regular caloric intake based on fast food, no exercise allowed
Study NCT03955666 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: PRV-3279 or placebo
Description: bi-specific antibody-based molecule
Study NCT04166981 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Instrumented posterolateral spine fusion.
Description: Posterolateral fusion with autologous and allogenic bone graft with supplementary pedicle screw fixation.
Study NCT04166981 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Non-instrumented posterolateral spine fusion.
Description: Posterolateral fusion with autologous and allogenic bone graft.
Study NCT03855319 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: SMR neurofeedback training to MCI
Description: The intervention consisted to increase the synaptic strengths and sensitivity within this network. Electroencephalography signals for SMR/theta training was recorded at channel Cz according to the international 10-20 system. Theta rhythm was also recorded and, in this case, SMR was stimulated while theta waves were suppressed.A 32 channels system (EEGDigitrcak Biofeedback plus module, Inc Elmiko Medical) was used for the SMR/theta Neurofeedback training.
Study NCT01525706 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ethanol and Paclitaxel Injection
Description: Endoscopic ultrasound will be used to locate and assess the pancreatic cyst. The fluid contents will be aspirated using a fine needle and sent for tumor marker analysis and cytology. With the needle maintained in the same position, 99% ethanol will be injected into the cyst. After 3-5 minutes of lavage, the entire volume of fluid will be removed from the cyst. The same volume of paclitaxel minus 1 mL \[3mg/ml diluted in normal saline from original concentration of 6mg/mL\] will be injected and left in the cyst. The needle is then retracted and the procedure completed. Patients will receive oral prophylactic antibiotics for 5 days after the procedure. Clinical follow up with MRI imaging with be done at 6, 12, 18, and 24 months. For those with a persistent cyst at 12 months, a repeat EUS FNI procedure will be done.
Study NCT04262310 — intervention group
Intervention type: OTHER
Intervention: Small Bowel and Colonic Permeability Test
Description: small bowel and colonic permeability based on oral probe molecules and urine excretion in 60 healthy white, female and male adults aged 18-70y
Study NCT02100865 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Solar powered oxygen
Study NCT03179228 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Prostate Embolization
Description: Embolization of the prostate with acrylic polymer microspheres impregnated with porcine gelatin
Study NCT02125175 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Hypofractionated IMRT boost Radiotherapy
Study NCT00108225 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: LoBag Diet - test phase
Description: A Low Biologically Available Glucose (LOBAG30), weight maintaining diet consisting of 30% carbohydrate, 30% protein, 40% fat will be provided to subjects for 5 weeks.
Study NCT00108225 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: LoBAG Diet - control phase
Description: A control, weight maintaining diet consisting of 55% carbohydrate, 15% protein, 30% fat will be provided to subjects for 5 weeks
Study NCT04074642 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Neurosurgery
Description: adenoma removal
Study NCT04328844 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: IOA-244
Description: IOA-244 will be administered orally once daily (QD)
Study NCT04328844 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Avelumab Injection
Description: Avelumab will be administered IV every 2 weeks
Study NCT04328844 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pemetrexed
Description: Pemetrexed will be administered IV every 3 weeks
Study NCT00708383 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: 10% SSS embryo culture medium protein supplementation
Description: 10% SSS in addition to the 0.5% HSA already in the culture medium.
Study NCT00708383 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: 0.5% HSA embryo culture medium protein supplementation
Description: 0.5% HSA in the culture medium
Study NCT01292512 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Prognostic screening for complicated grief
Description: Patients in the intervention group are prognostically screened for development of complicated grief to identify those in need of help.
Study NCT01292512 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Prognostic screening for complicated grief
Description: Patients in the intervention group are prognostically screened for development of complicated grief to identify those in need of help.
Study NCT02100865 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Oxygen from cylinders
Study NCT00624871 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ascorbic acid (vitamin C)
Description: IV, 100 mg/kg/day, every day, for 3 days
Study NCT00624871 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ibuprofen
Description: PO, 10 mg/kg on day 1, 5 mg/kg/day on days 2 and 3 of life
Study NCT00624871 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Study NCT03782857 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Intervention
Description: Prevention of recurrent stroke, myocardial infarction and death Stepwise escalation of preventive medication Life style counselling including adherence to preventive treatment
Study NCT05305521 — intervention group
Intervention type: PROCEDURE
Intervention: transcrestal sinus floor elevation
Description: Under local anesthesia (articaine 4% with epinephrine 1:100.000), a minimally invasive full-thickness flap was elevated to expose the alveolar crest. Clinicians were left free to choose their preferred transcrestal antrostomy technique. After checking sinus membrane integrity with visual inspection and Valsalva maneuver, pre-heated (40°C) xenogeneic porcine bone substitute in gel form (Gel 40, Tecnoss, Giaveno, Italy) was injected through the crestal antrostomy in order to elevate the membrane and fill the sub-antral space. Duration of graft injection (in seconds) was recorded using a digital chronometer. Periapical intraoperative radiographs were taken to confirm membrane elevation of at least 10 mm.
Study NCT05305521 — intervention group
Intervention type: PROCEDURE
Intervention: Implant placement
Description: Simultaneous implant placement was performed when it was possible to achieve adequate primary stability in the residual crestal bone, otherwise crestal antrostomy was sealed by collagen sponges (Hemocollagene, Septodont, Saint-Maur-des-Fossés, France) and implant insertion was postponed.~Flaps were sutured with Sentineri technique and single stitches using synthetic monofilament
Study NCT04155983 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ropivacaine
Description: The drug will be administered in the same dosage in both arms. The location of the injection will vary by arm.
Study NCT01113710 — intervention group
Intervention type: DRUG
Intervention: Neupro®
Description: Neupro® is the exposure/intervention of interest in this non-interventional study.
Study NCT03090334 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: De-escalation
Description: Antifungal therapy will be stopped according with BG results
Study NCT03136783 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Development of the most specific physiologically relevant experimental patient models
Description: Development of the most specific physiologically relevant experimental patient models: organotypic culture of biopsies, reconstituted skin (equivalents of dermis with melanoma, dermis equivalents and epidermis with melanoma), and in vitro evaluation The response of tumor cells to different combinations of targeted therapy molecules
Study NCT03086239 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rovalpituzumab tesirine
Description: Intravenous
Study NCT02431676 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Metformin
Description: Participants will receive metformin, an oral medication for type 2 diabetes.Participants randomized to the metformin intervention will receive metformin up to 2,000 mg per day.Dosing can be flexible, two or three times per day with meals as tolerated for 12 months.
Study NCT02431676 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Coach Directed Behavioral Weight Loss
Description: Behavioral-based telephonic coaching with web-based support to promote healthy lifestyle and weight loss in overweight and obese adults.The goal of this intervention is to achieve at least 5% weight loss in the first six months of the intervention and maintain these improvements through month twelve by meeting dietary and exercise goals
Study NCT02431676 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Self-control weight loss
Study NCT04013672 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pembrolizumab
Description: 200 mg IV every 3 weeks
Study NCT04328844 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cisplatin
Description: Cisplatin will be administered IV every 3 weeks
Study NCT04328844 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ruxolitinib
Description: Ruxolitinib will be administered orally twice a day (BD)
Study NCT04013672 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SurVaxM
Description: 500 mcg per dose, dosed every two weeks for 4 doses and then every 3 months
Study NCT01737177 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bendamustine, Lenalidomide, Rituximab
Description: INDUCTION PHASE (COURSE 1-4)~* Bendamustine: 70 mg/m2 on day 2 and 3 every 28~* Lenalidomide: 10 mg/daily on day 1 to 14 of a 28 days course~* Rituximab: 375 mg/m2 on day 1 every 28 days; only for the first cycle in the induction phase will start on day 8~CONSOLIDATION PHASE (courses 5-6)~Patients in CR and PR at the end of the induction phase~* Lenalidomide: 15 mg/daily on day 1 to 21 of a 28 days course.~* Rituximab: 375 mg/m2 on day 1 every 28 days~MAINTENANCE PHASE (courses 7-24)~Patients in CR or PR at the end of the consolidation treatment with Lenalidomide until disease progression or unacceptable toxicity up to 18 months (from month 7 to month 24)~- Lenalidomide: 15 mg/daily on day 1 to 21 of a 28 days